Pfizer Stock News

Pfizer (PFE) closed the most recent trading day at $25.91, moving +0.19% from the previous trading session.

Pfizer has been struggling since its coronavirus vaccine sales started to fall. It's making a big move into cancer drugs, which should help it diversify.

Pfizer lost heaps of COVID-19 revenue, but a slate of new drugs could lead to steady gains for patient investors. Ares Capital is a well-managed business development company that offers investors a 9.

Pfizer has faced numerous challenges, including a decline in COVID-19 vaccine demand and high costs, but the worst is likely priced into the stock. The company is focusing on innovation and has ambiti

Pfizer's PEG ratio according to one widely used financial website is shockingly low. This low valuation metric raises questions.

Over the last twelve months, Pfizer's stock experienced a massive sell-off due to a massive revenue and EPS drop after the COVID-related spikes of 2021 and 2022. However, the company's financial perfo

Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.

With rising concerns in the market potentially forcing a strategic shift, investors may want to consider healthcare stocks. No matter what happens, people need access to health-related products and se

Pfizer's (PFE) RSV vaccine, Abrysvo, generates an immune response in a phase III study evaluating it in higher-risk adults aged 18 to 59, non-inferior to that in older adults.

Drug giant Pfizer has been investing big money into oncology in recent years. In a decade, the company's product mix may look significantly different than today.

A late-stage trial of Pfizer's RSV vaccine showed promising results in adults under 60 years old, suggesting the shot could help people as young as 18, the company announced Tuesday, amid an effort to

Pfizer Inc   (NYSE PFE) stock is up 1.7% at $27.04 at last check, following news a late-stage trial of its respiratory syncytial virus (RSV) vaccine Abrysvo generated an immune response in higher r

Pfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above and expectant mothers.

The stock market's been wobbly in the past couple of weeks, influenced by Federal Reserve officials' cautious stance on cutting interest rates. However, with a cooling job market, it's only a matter o

Ken Griffin's Citadel hedge fund more than quadrupled its stake in this stock in 2023 Q4. Griffin probably likes the stock because of its valuation, dividend, and surprisingly robust growth prospects.